Generated by AI
PepGen Inc. is a clinical-stage biotechnology company focused on developing oligonucleotide therapeutics for severe neuromuscular and neurologic diseases. The company’s work centers on its proprietary Enhanced Delivery Oligonucleotide platform, which is designed to improve the delivery, uptake, and activity of conjugated oligonucleotide medicines in targeted tissues. PepGen’s current pipeline includes investigational programs for conditions such as Duchenne muscular dystrophy and myotonic dystrophy type 1, with several candidates in clinical development and additional programs in earlier stages. By concentrating on genetic disorders with high unmet medical need, PepGen aims to advance precision therapeutics that address the underlying cause of disease rather than only managing symptoms. The company is headquartered in Boston, Massachusetts.
Website321 Harrison Avenue
Boston, MA, 02118
United States
The latest articles about PEPG.
2026-11-13. The following slide deck was published by PepGen Inc.
Summary of Nov 17's posts. Generated by AI.
Summary of Nov 12's posts. Generated by AI.
PepGen is rated a Buy, after phase 2 DM1 data show 46.5% mean splicing correction, supporting a potential FDA meeting in 2H 2027.
Summary of Nov 17's posts. Generated by AI.
Investors talking about PEPG also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.